BI(G)MED as a very novel method based on oral immunogenetical therapy to prevent and treat allergic diseases especially asthma

Gilbert Glady M.D., European Bio Immun (G)en Medicine Association

Abstract

Oral immunotherapy has become a recognized method and validated by numerous publications, and its use has developed in the current practice of an allergy clinic.It has also been identified as likely to result in fewer adverse reactions than other conventional treatments administered by the systemic route. We propose an innovative and even revolutionary methodology by some aspects still little known in common allergology, which allows a soft and progressive regulation of the main molecular disorders involved at an immunogenetic level in the pathophysiological mechanisms of the various allergic diseases currently listed. For this purpose, we first resort to a regulation taking place at the epigenetic level thanks to the introduction in our therapeuticmethodology of microRNAs used for their remarkable posttranscriptional regulatory action. All components of our cures are prepared in high dilutions to avoid any noxious side effects and administered per sublingual way. But the Bio Immuno(G)en Medicine – BI(G)MED in shortcut – is also holistic in that it does not just act in a regulating way on the immunogenetic mechanisms involved directly in the genesis of allergic diseases, but also search for neutralizing infectious, viral and bacterial and even fungal agents, which have a pernicious influence on the course of clinical allergic phenomena. To achieve this result the BI(G)MED uses a wide range of biological tests to measure the patient's reaction potential at the immunogenetic level and the impact of infectious agents in direct interaction with the immune system. The description of clinical cases of my private practice with their therapeutic modalities will make it possible to highlight the regulatory properties of this new method referring to the selfregulation potential inherent in cellular homeostasis.

Image




Figure 2 Highlights of the evidences in SLIT, from 2009 to 2013, the scientific basis for the updating of "Sublingual Immunotherapy: World Allergy Organization Position Paper 2009".

Recent Publications (minimum 5)

1. Lan F, Zhang N, Gevaert E, Zhang L, Bachert C. (2016) Viruses and bacteria in Th2- biased allergic airway disease Allergy Oct;71(10):1381-92.
2. Makatsori M, Calderon MA. (2014) Sublingual allergen immunotherapy for respiratory allergies: what is new? Expert Rev Clin Immunol. Dec;10(12):1641-7.
3. Normansell R, Kew KM, Bridgman AL.(2015) Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. Aug 28;(8):CD011293.
4. Pleskovic N, Bartholow A, Skoner DP (2014) Sublingual immunotherapy in children: the Recent experiences Curr Opin Allergy Clin Immunol. Dec;14(6):582-90.
5. Saporta D. (2016) Sublingual Immunotherapy: A Useful Tool for the Allergist in Private Practice. Biomed Res Int.;2016:9323804.
6. Suzaki H, Watanabe S, Pawankar R. (2013) Rhinosinusitis and asthma-microbiome and new perspectives Curr Opin Allergy Clin Immunol. Feb;13(1):45-9.



Biography

Gilbert GLADY has completed his MD at the age of 27 years from Strasbourg University of Medicine and postdoctoral studies from Besançon and Paris-Nord Universities of Medicine. He got during all these years an expertise in immunology and immunogenetics and developed also interest for alternative medicines. So he becames at 2010 the creator of the BI(G)MED method and director of EBMA, the european association for training the medical profession at the BI(G)MED. He has participated in numerous international congresses in the field of immuno-allergology, infectiology and oncology with posters and oral presentations.

Email: dr.glady68@gmail.com